Pharmaceuticals News and Research

RSS

Mylan subsidiary receives FDA approval for generic version of Neurontin Tablets

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Gabapentin Tablets USP, 600 mg and 800 mg, the generic version of Pfizer's Neurontin Tablets for the treatment of postherpetic neuralgia, a complication of shingles.

5 Jun 2010

Cardinal Health and UW collaborate to advance use of molecular imaging in clinical investigations and trials

Cardinal Health and the University of Washington (UW) today announced an innovative public-private collaboration designed to advance the use of molecular imaging in clinical investigations and trials.

4 Jun 2010

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Bayer HealthCare will present a combined analysis from Phase I and II clinical trials evaluating the safety and efficacy of one of its lead investigational cancer treatments, Alpharadin™ (radium-223 chloride), in castration-resistant prostate cancer (CRPC) that has spread to the bones (metastases).

4 Jun 2010

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Infinity Pharmaceuticals, Inc. today reported the results from its Phase 2 clinical trial of IPI-504, the company's i.v.-administered Hsp90 chaperone inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). Data reported show that IPI-504 demonstrated clinical activity in patients with NSCLC, in particular among patients with oncogenic anaplastic lymphoma kinase (ALK) gene rearrangements.

4 Jun 2010

Ascalon International signs license agreement with CerRx

Ascalon International Inc., a newly established oncology drug developer, today announced an agreement for an exclusive option to license CerRx Inc's intravenous fenretinide product.

4 Jun 2010

BioSpecifics' board authorizes $2 million common stock repurchase program

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its Board of Directors has authorized the repurchase of up to $2 million of its outstanding common stock. This decision reflects the Company's continued commitment to increasing value for its stockholders and its confidence that it will achieve its goals.

4 Jun 2010

Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER

Labopharm Inc. today commented on the outcome of the appeal by Purdue Pharma Products L.P. and the cross-appeal by Par Pharmaceutical Companies, Inc. of the decision of the United States District Court for the District of Delaware in August 2009 on patent-infringement litigation initiated by Purdue against Par relating to Ultram ER (tramadol hydrochloride extended-release tablets).

4 Jun 2010

Researchers induce memory of safety in brain of rats

Researchers have found a way to pharmacologically induce a memory of safety in the brain of rats, mimicking the effect of training. The finding suggests possibilities for new treatments for individuals suffering from anxiety disorders.

4 Jun 2010

Reprints Desk to sponsor and exhibit at two pharmaceutical marketing events

Derycz Scientific, Inc., a company that is pioneering a fresh way of facilitating the flow of information from content publishers to enterprise customers and their constituents, today announced that Reprints Desk, an award-winning provider of information services and content workflow solutions, will sponsor and exhibit at two pharmaceutical marketing events: Digital Pharma West, being held in San Francisco from June 28-30, 2010, and Digital Pharma East, being held in Philadelphia from October 18-20, 2010.

4 Jun 2010

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that two scientific abstracts on the activity of tranilast against key components of gout - high serum uric acid levels and monosodium urate crystal-induced inflammation - have been accepted for The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology, to be held in Rome, Italy, June 16-19, 2010.

4 Jun 2010

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Idera Pharmaceuticals, Inc. today announced the publication of data from studies of a dual agonist of Toll-like Receptor 7 and TLR8 in preclinical models of cancer. The Company created this first-in-class RNA-based dual agonist of TLR7 and TLR8 through its chemistry-based approach to identifying novel TLR-targeted drug candidates.

4 Jun 2010

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

Particle Sciences has expanded its Bioanalytic Service's offerings to include Dried Blood Spot LC/MS/MS analysis (DBS). DBS is a growing area of interest because of its advantages in sample collection, stability, and simplified storage requirements. By using DBS, sample collection and processing is greatly simplified resulting in decreased costs, increased safety and greater comfort for test subjects.

4 Jun 2010

USP, Ukrainian Centre sign agreement to improve quality of pharmaceuticals worldwide

With the mutual goal of improving the quality of pharmaceuticals worldwide, the U.S. Pharmacopeial Convention and the Ukraine Scientific Pharmacopoeial Centre for the Quality of Medicines have entered into an agreement to share standards for the quality, purity, strength and identity of medicines.

4 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

Merrimack's Phase 1/2 trial design of MM-111 in HER2 positive cancer to be presented at 2010 ASCO

Merrimack Pharmaceuticals, Inc. announced today that the design of their Phase 1/2 trial investigating the safety and tolerability of MM-111 in HER2 positive cancer patients will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4-8, 2010, in Chicago, Illinois.

4 Jun 2010

Research finding suggests possibilities for future treatment of anxiety disorders

Researchers at the University of Puerto Rico, School of Medicine have found a way to pharmacologically induce a memory of safety in the brain of rats. As reported in the June, 4 2010 issue of Science, administering brain-derived neurotrophic factor into the prefrontal cortex prevented rats from expressing fear to a tone that had been previously paired with a shock.

4 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

BSGI effective for evaluating unclear mammographic or ultrasound findings

Researchers at the Legacy Good Samaritan Hospital in Portland, Oregon presented data on the clinical use of Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging technique, at the American Society of Breast Surgeons Annual meeting in Las Vegas in April: Breast Specific Gamma Imaging Used As An Adjunct to Mammography.

4 Jun 2010

CHOC Children's receives royalty-free research license to certain StemCells' patents

StemCells, Inc. and the Children's Hospital of Orange County ("CHOC Children's") announced today that they have entered into an agreement that provides CHOC Children's with a royalty-free research license to certain of StemCells' patents. This license authorizes CHOC Children's to proliferate, maintain and use human neural stem cells for non-commercial purposes.

4 Jun 2010

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.

4 Jun 2010

Pharmaceuticals News and Research

Mylan subsidiary receives FDA approval for generic version of Neurontin Tablets

Cardinal Health and UW collaborate to advance use of molecular imaging in clinical investigations and trials

Bayer to present Phase I and II clinical trial data of Alpharadin in CRPC at 46th ASCO

Infinity announces Phase 2 clinical trial results of IPI-504 for NSCLC

Ascalon International signs license agreement with CerRx

BioSpecifics' board authorizes $2 million common stock repurchase program

Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER

Researchers induce memory of safety in brain of rats

Reprints Desk to sponsor and exhibit at two pharmaceutical marketing events

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

Preclinical data of dual TLR7 and TLR8 agonist in cancer published

Particle Sciences adds Dried Blood Spot Analysis capability to Analytic Services offerings

USP, Ukrainian Centre sign agreement to improve quality of pharmaceuticals worldwide

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Merrimack's Phase 1/2 trial design of MM-111 in HER2 positive cancer to be presented at 2010 ASCO

Research finding suggests possibilities for future treatment of anxiety disorders

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

BSGI effective for evaluating unclear mammographic or ultrasound findings

CHOC Children's receives royalty-free research license to certain StemCells' patents

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News